MASS 908 Devices Inc

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

 

Date of Report (Date of Earliest Event Reported): August 6, 2024

 

 

908 Devices Inc.

(Exact name of registrant as specified in its charter)

 

 

Delaware		001-39815		45-4524096
(State or other jurisdiction of incorporation)		(Commission File Number)		(I.R.S. Employer Identification No.)

 

645 Summer Street

Boston, MA  02210

(Address of principal executive offices, including zip code)

 

(857) 254-1500
(Registrant’s telephone number, including area code)

 

Not Applicable
(Former name or former address, if changed since last report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act: 

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value $0.001 per share	MASS	The NASDAQ Global Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 ( §230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company  x

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ¨

 

 

 

Item 2.02

Results of Operations and Financial Condition.

 

On August 6, 2024, 908 Devices Inc. (“908 Devices”) announced its financial results for the second quarter ended June 30, 2024. A copy of the press release is being furnished as Exhibit 99.1 to this Report on Form 8-K.

 

The information contained in Item 2.02 of this Current Report on Form 8-K is being furnished and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section and shall not be incorporated by reference in any filing under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

 

Item 9.01	Financial Statements and Exhibits.
(d)   Exhibits:

 

Exhibit
No.		Description
99.1		Press release issued by 908 Devices on August 6, 2024
104		Cover Page Interactive Data File (embedded within the inline XBRL document)

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: August 6, 2024	908 Devices Inc.
	By:	/s/ Michael S. Turner
		Name: Michael S. Turner
		Title: Chief Legal and Administrative Officer

 

 

Exhibit 99.1

 

 

908 Devices Reports Second Quarter 2024 Financial Results and Reiterates 2024 Revenue Outlook

 

Revenue increases 16% compared to prior year, driven by newly acquired handheld products

 

BOSTON – August 6, 2024 – 908 Devices Inc. (Nasdaq: MASS), a pioneer of purpose-built handheld and desktop devices for chemical analysis, today reported financial results for the quarter ended June 30, 2024.

 

"We delivered solid execution on a multitude of fronts in the quarter, including the acquisition and integration of RedWave Technology into our company. With an expanded handheld portfolio, we are now supporting both our new and existing forensics customers more efficiently,” said Kevin J. Knopp, CEO and Co-founder. “We also maintained a strong focus on operational excellence during the quarter and have begun to see early benefits of our increasing scale.”

 

Recent Highlights

 

●	Revenue of $14.0 million for the second quarter 2024, increasing 16% compared to the second quarter 2023

 

o

Handheld revenue was $11.1 million, increasing 26% year over year

 

o

Desktop revenue was $2.9 million, decreasing 9% year over year

 

o

Recurring revenue was $5.3 million, increasing 33% year over year

 

o

38% of revenue was recurring revenue, driven by service and REBEL consumables

 

●	Gross margin increased 490 basis points to 53% for the second quarter 2024, partly due to timing of production but also as a result of scale across the business including higher handheld service revenues

 

●	Launched a quantification package that enhances our XplorIR handheld gas and vapor analyzer, enabling first responders to now identify and quantify nearly 5,000 airborne chemicals

 

●	Completed the commercial integration of RedWave Technology

 

●	Presented 13 posters at the American Society for Mass Spectrometry (ASMS) conference and were collaborators on three oral presentations with researchers from the University of Wisconsin-Madison and the National Institute for Bioprocessing Research and Training (NIBRT)

 

●	Appointed Michele M. Leonhart, former administrator of the U.S. Drug Enforcement Administration, to our Board of Directors

 

Second Quarter 2024 Financial Results

 

Revenue was $14.0 million for the three months ended June 30, 2024, a 16% increase over the prior year period. This was primarily driven by an increase in handheld devices revenue offset by a decrease in desktop devices revenue. The installed base grew to 3,067 devices with 143 handheld devices and 10 desktop devices placed during the second quarter 2024. Recurring revenue represented 38% of total revenues in the quarter.

 

Gross profit was $7.4 million for the second quarter of 2024, compared to $5.8 million for the corresponding period in the prior year. Gross margin was 53% as compared to 48% for the corresponding prior year period. Adjusted gross profit was $8.1 million for the second quarter of 2024, compared to $6.0 million for the corresponding period in the prior year. Adjusted gross margin was 58% as compared to 50% for the corresponding prior year period.

 

Operating expenses were $21.0 million for the second quarter of 2024, compared to $16.7 million for the corresponding prior year period. This increase was driven by $1.9 million in acquisition and integration costs, the inclusion of two months of operating expenses related to our RedWave acquisition, and stock-based compensation.

 

Net loss was $12.5 million for the second quarter of 2024, compared to $9.3 million for the corresponding prior year period. Adjusted EBITDA was a loss of $7.3 million for the second quarter of 2024, compared to a loss of $7.7 million for the second quarter of 2023.

 

Cash, cash equivalents and marketable securities were $77.4 million as of June 30, 2024 with no debt outstanding.

 

 

2024 Guidance

 

908 Devices continues to expect full year reported 2024 revenue to be in the range of $63.0 million to $65.0 million, representing 25% to 29% growth over full year 2023. This includes $11 million of expected revenue from RedWave Technology, representing 8 months of ownership.

 

Webcast Information

 

908 Devices will host a conference call to discuss the second quarter 2024 financial results before market open on Tuesday, August 6, 2024 at 5:30 am Pacific Time / 8:30 am Eastern Time. A webcast of the conference call can be accessed at https://ir.908devices.com/news-events/events. The webcast will be archived and available for replay for at least 90 days after the event.

 

About 908 Devices

 

908 Devices is revolutionizing chemical analysis with its simple handheld and desktop devices, addressing life-altering applications. The Company’s devices are used at the point-of-need to interrogate unknown and invisible materials and provide quick, actionable answers to directly address some of the most critical problems in forensics, bioprocessing, pharma / biopharma, life sciences research and adjacent markets. The Company is headquartered in the heart of Boston, where it designs and manufactures innovative products that bring together the power of complementary analytical technologies, microfluidic sampling and separations, software automation, and machine learning.

 

Non-GAAP Measures of Financial Performance

 

To supplement the Company’s financial statements, which are presented on the basis of U.S. generally accepted accounting principles (GAAP), the following non-GAAP measures of financial performance are included in this release and presented with detailed reconciliations to comparable GAAP financial results in the tables below:

 

	●	Adjusted Gross Profit is defined as gross profit excluding intangible amortization, acquisition and integration costs, restructuring charges (including the costs of severance), and non-cash expenses related to stock-based compensation.
	●	Adjusted Gross Margin is defined as Adjusted Gross Profit expressed as a percentage of total revenue.
	●	Adjusted EBITDA is defined as net loss excluding other income, benefit for income taxes, depreciation, intangible amortization, acquisition and integration costs, restructuring charges (including the costs of severance), non-cash expenses related to stock-based compensation, and costs associated with contingent consideration related to the Company’s acquisitions and for which the conditions for payment have not yet been achieved.

 

The Company’s non-GAAP financial results presented in this earnings release exclude certain costs that management believes do not have a direct correlation to future business operations, nor do the resulting charges recorded accurately reflect the performance of ongoing operations for the period in which such charges are recorded, nor do the resulting charges recorded accurately reflect the anticipated cash flows of ongoing operations, and as such, excluding these costs allows management to understand and evaluate core operating performance and trends. However, as there are no standardized methods of calculating these non-GAAP financial measures, the Company’s methods may differ from those used by other companies in its industry, and accordingly, the use of these measures may not be directly comparable to similar measures used by others, thus limiting their usefulness for purposes of comparison. Furthermore, these non-GAAP measures have certain limitations since they do not include the impact of certain expenses and cash flows that are reflected in the Company’s GAAP financial results. Accordingly, when analyzing the Company’s operating performance and guidance, investors should not consider non-GAAP measures in isolation or as a substitute for, or superior to, comparable financial measures prepared in accordance with GAAP. Rather, the Company believes that these non-GAAP financial measures, when viewed in addition to and not in lieu of reported GAAP financial results, provide investors with additional meaningful information to assess financial performance and trends, enable comparison of financial results between periods, and allow for greater transparency with respect to key metrics utilized internally in analyzing and operating the Company’s business.

 

 

Forward Looking Statements

 

This press release includes “forward looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts are forward-looking statements, including, without limitation, statements regarding the Company’s future revenue and growth. Words such as “may,” “will,” “expect,” “plan,” “anticipate,” “estimate,” “intend” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These forward-looking statements are based on management’s current expectations and involve known and unknown risks, uncertainties and assumptions which may cause actual results to differ materially from any results expressed or implied by any forward-looking statement, including the risks outlined under “Risk Factors” and elsewhere in the Company’s filings with the Securities and Exchange Commission which are available on the SEC's website at www.sec.gov. Additional information will be made available in our annual and quarterly reports and other filings that we make from time to time with the SEC. Although the Company believes that the expectations reflected in its forward-looking statements are reasonable, it cannot guarantee future results. The Company has no obligation, and does not undertake any obligation, to update or revise any forward-looking statement made in this press release to reflect changes since the date of this press release, except as may be required by law.

 

Investor Contact:

Carrie Mendivil

IR@908devices.com

 

Media Contact:
Barbara Russo
brusso@908devices.com

 

 

908 DEVICES INC.

Condensed Consolidated Statements of Operations

(in thousands, except share and per share amounts)

(unaudited)

 

		Three Months Ended								Six Months Ended
		June 30,								June 30,
		2024				2023				2024				2023
Revenue:
Product revenue		$	10,266			$	9,595			$	17,499			$	16,617
Service revenue			3,681				2,354				6,439				4,594
Contract revenue			100				145				100				370
Total revenue			14,047				12,094				24,038				21,581
Cost of revenue:
Product cost of revenue			4,732				4,800				7,942				8,586
Service cost of revenue			1,823				1,448				3,601				2,718
Contract cost of revenue			74				52				74				99
Total cost of revenue			6,629				6,300				11,617				11,403
Gross profit			7,418				5,794				12,421				10,178
Operating expenses:
Research and development			6,381				5,525				12,171				10,923
Selling, general and administrative			14,597				11,208				26,498				23,211
Total operating expenses			20,978				16,733				38,669				34,134
Loss from operations			(13,560	)			(10,939	)			(26,248	)			(23,956	)
Other income, net			943				1,522				2,644				1,955
Loss from operations before income taxes			(12,617	)			(9,417	)			(23,604	)			(22,001	)
Benefit for income taxes			69				71				139				122
Net loss		$	(12,548	)		$	(9,346	)		$	(23,465	)		$	(21,879	)
Net loss per share attributable to common stockholders		$	(0.37	)		$	(0.29	)		$	(0.70	)		$	(0.68	)
Weighted average common shares outstanding			34,061,933				32,199,156				33,386,413				32,083,122

 

 

908 DEVICES INC.

Condensed Consolidated Balance Sheets

(in thousands)

(unaudited)

 

		June 30,				December 31,
		2024				2023
Assets
Current assets:
Cash, cash equivalents and marketable securities		$	77,383			$	145,682
Accounts receivable, net			10,987				8,989
Inventory			18,589				14,938
Prepaid expenses and other current assets			3,485				4,181
Total current assets			110,444				173,790
Operating lease, right-of-use assets			5,904				6,233
Property and equipment, net			3,556				3,342
Goodwill			40,220				10,367
Intangible, net			47,298				7,860
Other long-term assets			1,352				1,389
Total assets		$	208,774			$	202,981
Liabilities and Stockholders' Equity
Current liabilities:
Accounts payable and accrued expenses		$	7,610			$	9,904
Deferred revenue			11,954				10,629
Operating lease liabilities			2,153				2,016
Total current liabilities			21,717				22,549
Deferred revenue, net of current portion			9,528				3,929
Other long-term liabilities			21,170				11,012
Total liabilities			52,415				37,490
Total stockholders' equity			156,359				165,491
Total liabilities and stockholders' equity		$	208,774			$	202,981

 

 

908 DEVICES INC.

Reconciliations of GAAP to Non-GAAP Financial Measures

(Unaudited, amounts in thousands, except percentage and per share data)

In all tables below, totals may not add due to rounding

 

Reconciliation from Gross Profit (GAAP) to Adjusted Gross Profit (Non-GAAP) and Margin Percentage:

 

		Three Months Ended								Six Months Ended
		June 30,								June 30,
		2024				2023				2024				2023
Gross Profit (GAAP)		$	7,418			$	5,794			$	12,421			$	10,178
Intangible amortization			530				107				637				213
Acquisition and integration costs			-				-				-				-
Restructuring			-				-				-				-
Stock-based compensation			202				140				373				255
Adjusted Gross Profit (Non-GAAP)		$	8,150			$	6,041			$	13,431			$	10,646
Gross Margin Percentage (GAAP)			53	%			48	%			52	%			47	%
Adjusted Gross Margin Percentage (Non-GAAP)			58	%			50	%			56	%			49	%

 

Reconciliation from Net Loss (GAAP) to Adjusted EBITDA (Non-GAAP):

 

		Three Months Ended								Six Months Ended
		June 30,								June 30,
		2024				2023				2024				2023
Net Loss (GAAP)		$	(12,548	)		$	(9,346	)		$	(23,465	)		$	(21,879	)
Adjustments:
Other income, net			(943	)			(1,522	)			(2,644	)			(1,955	)
Benefit for income taxes			(69	)			(71	)			(139	)			(122	)
Depreciation			500				368				918				738
Intangible amortization			693				219				913				437
Acquisition and integration costs			1,950				-				1,950				-
Restructuring			-				-				-				524
Stock-based compensation			3,096				2,578				5,739				4,744
Contingent consideration			-				65				-				230
Adjusted EBITDA (Non-GAAP)		$	(7,321	)		$	(7,709	)		$	(16,728	)		$	(17,283	)

 

 

v3.24.2.u1

Cover	Aug. 06, 2024
Cover [Abstract]
Document Type	8-K
Amendment Flag	false
Document Period End Date	Aug. 06, 2024
Entity File Number	001-39815
Entity Registrant Name	908 Devices Inc.
Entity Central Index Key	0001555279
Entity Tax Identification Number	45-4524096
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	645 Summer Street
Entity Address, City or Town	Boston
Entity Address, State or Province	MA
Entity Address, Postal Zip Code	02210
City Area Code	857
Local Phone Number	254-1500
Written Communications	false
Soliciting Material	false
Pre-commencement Tender Offer	false
Pre-commencement Issuer Tender Offer	false
Title of 12(b) Security	Common Stock, par value $0.001 per share
Trading Symbol	MASS
Security Exchange Name	NASDAQ
Entity Emerging Growth Company	true
Elected Not To Use the Extended Transition Period	false

---